Leading dermatologists offered their recommendations on the top acne scar treatments. See what they’re recommending to their patients and why. To improve patient care and outcomes, leading dermatologists offered their recommendations on acne scar treatments.
Nestlé Skin Health has announced that Humberto Antunes, Nestlé’s CEO, will leave the company at the end of October, and will be replaced by Paul Navarre. Antunes joined Galderma, Nestlé Skin Health’s medical solutions business, in 1997, took over Galderma worldwide operations in 2004 and was named Nestlé Skin Health CEO in 2014, according to a press release.
Allergan CEO and President Brent Saunders believes in a “social contract” that balances the cost of developing new medications with affordability. In a blog post on the Allergan website, Saunders noted that companies that aggressively raise prices on medications or needed items have “violated this social contract.”
Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved by the U.S. Food and Drug Administration in February 2016.
Allergan plc announced in a press release that its board of directors has authorized a share repurchase program of up to $10 billion of the company's common stock.
The FDA’s approval of Allergan plc’s Aczone Gel, 7.5% as a once-daily topical treatment for patients with acne was a recent development reported on Healio.com/Dermatology. Other recent developments included research presented at the American Academy of Dermatology Annual Meeting on acne treatment and the public’s misconceptions of patients with acne.
Allergan plc announced that the FDA has approved Aczone Gel, 7.5% as once-daily topical treatment for patients aged 12 years and older with acne. Aczone Gel, 7.5% (dapsone), a prescription medicine, was tested in two identical 12-week studies.